HT9425-24-RFI-LBA-01.pdf

Request for Information (RFI)

1. RFI Number: HT9425-24-LBA-RFI-01

2. RFI Title: Poloxamer Gel

3. Agency: The United States Air Force (USAF) 59th Medical Wing, Science and Technology Office

4. Office: The United States Air Force (USAF) 59th Medical Wing, Science and Technology Office

5. Contracting Office: United States Army Medical Research Acquisition Activity (USAMRAA), Fort Detrick, Frederick, MD.

6. Location: Joint Base San Antonio – Lackland Air Force Base, Texas

7. Background: Military personnel who experience traumatic combat wounds and require hospitalization for medical management are at high risk of developing combat-related extremity wound infections (CEWI). The aims of this study are to develop a novel thermoresponsive, bioadhesive, antibiotic gel that can be applied by topical spray directly to open combat-related wounds during hospitalization to prevent infection. CEWIs are often caused by antibiotic resistant bacteria, including Acinetobacter baumanii and Methicillin-resistant Staphylococcus aureus (MRSA). The choice of omadacycline and polymixin B to include in the gel is specifically to target such pathogens. Because of their unique pharmaceutical and antibiofilm properties, attempt will be made to utilize poloxamer vehicles in the gel. Lastly, this study aims to evaluate effects of the antibiotic gel to prevent infection in a modified animal model of wound infection.

The USAF 59th Medical Wing, Science and Technology Office requires a contract for the Advancement of Military Medicine for a research and development requirement.

8. Objective and Purpose: The objective is to develop a novel thermoresponsive, bioadhesive, antibiotic gel and evaluate effects of the antibiotic gel to prevent infection in a modified animal model of wound infection. The objectives will involve product development and animal model experiments using the product developed.

9. Information Requested in Capability Statement:

• Describe the company’s ability to provide research and development of the specific gel to prevent infection.

• Describe the company’s expertise in the areas of research and development and understanding of the Advancement of Military Medicine currently at 59th MW.

10. North American Industry Classification System (NAICS) Code: The NAICS code for this potential action is: 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

11. Response Due Date: Interested parties should submit their RFI response electronically by 12:00 pm Eastern on 19 April 2024 via e-mail to Ms. Lindsey Arthur at lindsey.b.arthur2.civ@health.mil.

12. Instructions to Responders:

12.1 The Government appreciates responses from all capable and qualified sources.

12.2 The Government welcomes input and will accept questions pertaining to this RFI;

however, the Government reserves the right to answer or not answer all questions pertaining to this RFI. Only one set of questions per vendor will be accepted. Telephone requests will not be entertained.

12.3 The subject header of the e-mail for submission of questions and/or the RFI response shall be: HT9425-24-LBA-RFI-01.

12.4 Interested firms should submit a response (Capability Statement) that demonstrates the Offeror’s capabilities identified in this RFI and shall also provide verification that the vendor is an authorized reseller of the BD product. The Capability Statement shall not exceed five (5) typed pages; additional sheets for cover page, table of contents, tables, and charts will not be counted toward page limitation.

12.5 Fill in the below table when responding to this Sources Sought / RFI.

Question Answer RFI Number Company Name Company Address Point of Contact Phone Number E-mail Address Tax Identification Number (TIN) Cage Code

DUNS

Company Web Page Company Location(s) Company is / is not a Small Business Company is / is not SAM Registered Other Classifications (e.g. 8(a), HubZone, Woman-Owned, Veteran-Owned, Service- Disabled Veteran-Owned)

If 8(a), date that the company graduates from the program.

13. Disclaimer and Important Notes:

mailto:lindsey.b.arthur2.civ@health.mil

In accordance with Federal Acquisition Regulation (FAR) 15.201, "Exchange with industry before receipt of proposals," and FAR 52.215-3, "Request for information (RFI) or Solicitation for Planning Purposes (SFP)," this RFI is for information and planning purposes only, at this time, and shall not be construed as a solicitation or obligation on the part of the USAMRDC. The purpose of this RFI notice is to gain market knowledge.

This RFI is not expected to be a Request for Proposal or Invitation for Bid, nor does it restrict the Government to an ultimate acquisition approach. The Government is not obliged to award a contract or otherwise pay for the information provided in the responses received.

The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its responses are complete and sufficiently detailed to allow the Government to determine the organization's solution. Responders are advised that the Government is under no obligation to acknowledge receipt of the information received, or to provide feedback to respondents regarding any information submitted.

After a review of the responses received, a pre-solicitation synopsis and solicitation may be published on SAM.gov. At this time, no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS PLEASE. It is the responsibility of any potential vendor to monitor SAM.gov for the release of any solicitation or synopsis.

Responses to this notice will not be considered adequate responses to a solicitation.

14. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in submitted responses. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

Original Point of Contact (POC): Lindsey Arthur, lindsey.b.arthur2.civ@health.mil mailto:lindsey.b.arthur2.civ@health.mil